Medtronic earnings analysis: questions answered and next catalysts

Medtronic reported Q1 FY27 revenue of $9.8bn, up 13.7% YoY, and raised its FY27 outlook. Cardiovascular segment led growth, with EPT revenues at $2.2bn, up 29.5% YoY. Shares rose 1.5% post-earnings. According to the company, it expects to outpace the market in Q2.

Medtronic PLC (MDT) reported Q1 2027 earnings with strong revenue growth boosted by an extra selling week, but faces margin pressures. The company raised revenue guidance by 50 basis points but expects foreign exchange headwinds. Management discussed growth drivers, investments, and the upcoming diabetes business separation.

Medtronic (MDT) invested $80m in Pi-Cardia Ltd, with an option to acquire the company for up to $210m. The deal includes potential earn-outs and makes Medtronic the exclusive distributor of Pi-Cardia's ShortCut device. MDT shares rose 4.81% on the day, but the move may also reflect upcoming earnings. The investment is part of Medtronic's strategy to bolster its TAVR business.

Medtronic (MDT) and its diabetes spinoff Minimed (MMED) raised full-year guidance, leading to a stock rally. Medtronic reported 13.7% organic sales growth, exceeding forecasts in cardiovascular and medical-surgical sectors, while neuroscience met expectations, according to Evercore ISI analyst Vijay Kumar.

Medtronic (NYSE: MDT) reported Q1 FY27 revenue of $9.8B, up 13.7% YoY, and raised FY27 guidance. Key growth areas include Cardiovascular (18.9%) and Neuroscience (9.3%). The company also announced strategic investments and partnerships. GAAP EPS was $1.14, non-GAAP EPS was $1.45.

Medtronic (MDT) reported Q1 earnings, highlighting 15% growth in Cardiac Rhythm Management and 9% in Neuroscience. The company expects 6% organic revenue growth in Q2 and adjusted EPS of $1.32-$1.34. Medtronic also announced a $700M investment in Cornerstone Robotics' Sentire Surgical System. Diabetes revenue grew 15%, with plans to separate the business by fiscal year-end.